AI assistant
Sending…
Qualigen Therapeutics, Inc. — Director's Dealing 2021
May 17, 2021
35251_dirs_2021-05-17_0e76c1f5-c200-4d5f-8fcf-4246d9f491f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2021-05-17
Reporting Person: ARSHAD TARIQ (SVP/Chief Medical Officer)
More from Qualigen Therapeutics, Inc.
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 14
Annual Report
2026
Mar 30
Regulatory Filings
2026
Feb 27
Regulatory Filings
2026
Feb 17
Regulatory Filings
2026
Feb 2
Major Shareholding Notification
2026
Jan 29
Regulatory Filings
2026
Jan 6
Regulatory Filings
2025
Dec 16
Proxy Solicitation & Information Statement
2025
Dec 15